LONDON, UK – June 16, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Cancer Research Horizons and is pleased to announce the placements of Heather Preston, Richard Wooster and Hans Bishop as Non-Executive Directors (NEDs) to its Board.
Position Overview
As Product Manager, you will work closely with the COO, CCO and CEO to mature Broken String Bio’s existing products and evolve the product roadmap to support the successful development and launch of new offerings.
Isomorphic Labs is applying frontier AI to help unlock deeper scientific insights, faster breakthroughs, and life-changing medicines with an ambition to solve all disease.
The future is coming. A future enabled and enriched by the incredible power of machine learning. A future in which diseases are curtailed or cured starting with better and faster drug discovery.
Constructive Bio is a VC-backed biotechnology startup based in Whittlesford, Cambridge. Our unique technology turns living cells into biofactories, creating sustainable new materials and therapeutics. With full control of the genetic sequence and code, we are exploring chemical space previously unreached by natural biology.
About the role:
The Cross-Institute Partnerships Manager plays a key role in developing, coordinating and supporting strategic external partnerships that enhance the Institute's scientific environment and advance its strategic priorities.
Constructive Bio is a VC-backed biotechnology startup based in Whittlesford, Cambridge. Our unique technology turns living cells into biofactories, creating sustainable new materials and therapeutics. With full control of the genetic sequence and code, we are exploring chemical space previously unreached by natural biology.
Oxford, UK - 17 June 2026 - PrecisionLife has launched Biology Matters, a new podcast exploring how advances in biology, genomics, data science, and AI can help address one of healthcare's greatest challenges: chronic disease.
Amsbio has expanded its diverse range of recombinant and monoclonal antibodies to include over 10,000 new validated monospecific products in 15,000 formulations to support research in cancer, immunology, neuroscience, and signal transduction.
Strengthens Board with experienced industry executive, specializing in strategic planning, organizational leadership and commercial execution
Cresset has released Flare V12, a new version of its computer-aided drug design (CADD) solution for the discovery, design and optimization of small molecules. Flare V12 is focussed on improving access to Free Energy Perturbation (FEP) in drug discovery.
FEP is used to predict how strongly drug candidates bind to their targets, helping guide compound selection. However, despite its recognised accuracy, adoption has often been limited by computational cost, usability barriers and challenges in modeling complex chemical transformations.